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     INTRODUCTION 
  Treatment adherence to primaquine (PQ) for the radical 
cure of   Plasmodium vivax   infection is a major public-health 
concern in the Peruvian Amazon because of the predomi-
nance of this species in the region.  1   Although rarely fatal, 
the persistence of   P. vivax   in the liver can induce relapses 
for years after the initial infection, making adherence par-
ticularly relevant to eliminate the latent hypnozoite reser-
voir after symptoms abate.  2   In 2001, adherence problems to 
PQ led the Peruvian National Malaria Control Program to 
shorten the length of the treatment from a 14-day to a 7-day 
PQ course and to increase the daily dose from 0.25 to 0.5 
mg/kg/day. Nevertheless, despite the simpler therapeutic pro-
tocol,   P. vivax   malaria incidence in the Peruvian Amazon 
region remained high with recurrent parasitemia after treat-
ment in a high proportion of cases (T. Grande Montalvo and 
V. Soto, personal communication). Adherence, therefore, 
remains a key factor for effective malaria control, because it 
is directly related to treatment failure and the possible spread 
of resistant malaria strains. Furthermore, when patients do not 
access the right treatment, this results in poor health outcomes, 
lowering life quality and increasing medical costs.  3,  4  
  Little is known, however, about patients’ motives for adher-
ence or non-adherence in non-trial settings.  5   The objectives of 
the present study were to evaluate patient adherence to the 
7-day PQ course and provide additional qualitative data on 
factors influencing the adherence process in local communi-
ties of the Peruvian Amazon. 
   METHODS 
  Study  site.     The study was conducted in the catchment area 
of the Paujil and Cahuide Health Centers (HC) in the district 
of San Juan situated along the road connecting Iquitos city to 
the small port city of Nauta (  Figure 1  ), in the department of 
Loreto belonging to the Peruvian Amazon. Malaria distribution 
in Loreto is highly heterogeneous and contains foci of high 
incidence, such as the district of San Juan, which reported in 
2007 the highest number of cases in the region (total of 4,075 
for a population of 108,353).  1  Malaria transmission is perennial 
with a peak during the rainy season between November and 
May. All age groups are at risk, although adults are more so 
than children, and most infections are symptomatic.  6  –  8   The 
main vector is   Anopheles darlingi  , a highly anthropophilic 
species that recently (1990s) spread to this region because of 
new settlements and increasing forest exploitation.  9  ,  10  
     All communities are situated in the vicinity of the Itaya and 
Nanai Rivers and are within a 15-km range of the HC, and 
most are directly accessible by road.  11   Nevertheless, accessibil-
ity problems are common during the rainy season and persist 
year round for communities that can only be reached by boat 
because of a lack of transportation and high fuel prices. 
   Study  population.     The population in the study area was 
estimated at 5,239 inhabitants in 2007, and it mainly consists 
of mestizos, which refers to all Peruvians that cannot be 
clearly identified as belonging to any ethnic minority popu-
lation. Local subsistence strategies include slash and burn 
agriculture, fishing, hunting, and small-scale carbon production. 
Occasionally, people also engage in fish farming, logging, small 
commercial activities, and salaried employment as grounds’ 
keepers or cultivators for institutions, farms, and enterprises 
belonging to wealthier Iquitos residents. 
  Traditionally, the local population uses non-impregnated 
bed nets made of white woven cotton or tocuyo.  12   Long-lasting 
insecticidal nets were distributed with the Global Fund’s sup-
port just before the start of the present study in 2007.  13   Anti-
malaria treatment is provided free of charge after microscopy 
diagnosis at the Paujil and Cahuide HCs. Treatment of   P. vivax  
consists of 3 days of chloroquine (CQ; total = 25 mg/kg) and 
7 days of PQ (0.5 mg/kg/day), and it is administered without 
prior screening for G6PD deficiency, which is not considered 
prevalent in the area, although no formal reports have been 
published.  14   According to official guidelines,   P. vivax   patients 
are expected to report daily to the HC (except on Sundays) 
to receive their treatment doses, which are supervised by 
the health staff (Sunday doses are given 1 day in advance). 
However, in practice, patients are only asked to return to the 
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HC two times: at the end of the CQ treatment to collect the 
remaining doses of PQ and at the end of the PQ treatment for 
a final blood smear. 
  Most local communities have a trained volunteer commu-
nity health worker called  Promotor de Salud  able to take blood 
smears. After microscopic diagnosis at the HC, the health pro-
moter is expected to directly observe the intake of treatment 
for those unable to go to the HC. 
   Research  strategy.     The present research was ancillary to a 
larger ongoing cohort study on   P. vivax   morbidity after radical 
cure treatment, which was carried out in the framework of an 
institutional collaboration between the Institute of Tropical 
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Medicine (ITM) Antwerp-Belgium and the ITM Alexander 
von Humboldt (ITM-AvH) Lima-Peru.  15   The present targeted 
ethnography was designed to get a quantitative estimation of 
adherence to the current 7-day CQ-PQ regimen of microscop-
ically confirmed  P. vivax  malaria cases and to provide qualitative 
background information on treatment adherence and related 
decision-making factors in the local context. Considering 
the inherent reporting bias in response rates to adherence-
related questions, methodological triangulation (the use of 
various methods and techniques to refine and test particular 
interpretations and hypotheses) was used, combining qualitative 
data obtained during field work and quantitative data both from 
patients’ medical records at the HCs and from an additional 
survey administered to a random sample of previously treated 
vivax patients in their respective communities. Treatment 
adherence was defined as the proportion of patients that had 
actually completed the 7-day treatment as prescribed. Health-
system performance and quality-of-case management factors 
were not included. 
   Qualitative  data  collection.     During field work, the following 
research techniques were combined. Participant observation, 
including reiterated informal interviews with key and general 
informants, was carried out in 10 communities: El Dorado, 
13 de Febrero, Nuevo Horizonte, Ex-Petroleros, 12 de Abril, 
Cahuide, Villa Buen Pastor, Paujil, 24 de Junio, and El Triunfo. 
Informal conversations were not recorded. Notes were kept of 
the most relevant observations and conversations. Interviews 
were recorded and transcribed. When recording was not 
considered appropriate because of the sensitivity of the subject 
discussed or the informality of the conversation, notes were 
taken immediately after the interview. The interviews were 
held in the selected above-mentioned locations, representing 
a sufficient number of respondents to get a coherent picture of 
the local context and social setting. 
   Sampling.     Sampling for all informal and formal interviews 
was purposive.  16  –  19   Informants were selected according to 
relevant variables such as gender, age, subsistence strategy, 
locality, adherence, etc. to allow for maximum variation in the 
sample. Sampling techniques included respondent-driven or 
snowball sampling to improve data reliability.  20  ,  21  
   Quantitative  data  collection.     Two sources of quantitative 
data were combined to assess treatment adherence. 
    Medical records from HCs.    All  P. vivax   patients identified at 
the Paujil and Cahuide HCs between January 2005 and July 
2007 were anonymously recorded (using only code numbers) 
with the total treatment dose delivered by the HC. Additionally, 
vivax cases belonging to the Paujil and Cahuide HCs catchment 
area that had reported to neighboring HCs or the Iquitos 
Hospital were included in the database. For each patient, the 
total dose delivered at the beginning and after the completion 
of the CQ treatment was recorded in the database. Because 
these figures only related to the treatment provided by health 
services but not to treatment intake, a random sample of the 
above-mentioned patients was interviewed on the actual 
number of doses taken. 
   Patient-adherence  survey.    A sample of 185 vivax malaria 
patients was randomly selected from the HC database, and to 
minimize recall bias, the selection was limited to patients 
identified within the year before the study (i.e., July 2006 to 
July 2007). Patients were visited at home by the study team, 
and after oral informed consent, a structured, closed 
questionnaire was administered (for children < 18 years old, 
the questionnaire was administered to parents/guardians). The 
survey examined delay before consultation at the HC, produc-
tivity time loss because of the malaria episode, adher  ence to 
current radical treatment, reasons to interrupt treat  ment, and 
the alteration or combination of treatment with traditional 
remedies and home treatment. 
    Data  analysis.     Qualitative  data.    Qualitative data were 
entered and analyzed using N/Vivo Qualitative Analysis 
software (QSR International Pty Ltd., Cardigan, UK). The 
analysis was a flexible and iterative process; preliminary 
data obtained from different techniques were entered and 
analyzed to generate temporary results. Further research was 
then conducted to confirm or refute these temporary results 
until saturation was reached and data could be theoretically 
supported. 
   Quantitative  data.    All quantitative data were entered, 
cleaned, and analyzed in Epi Info 6.04 (Centers for Disease 
Control, Atlanta, GA; World Health Organization, Geneva, 
Switzerland). Summary statistics were computed using means 
or medians as appropriate for continuous variables and 
proportions for categorical variables. The main outcome vari-
able was treatment adherence. Secondary outcome variables 
were perceived causes of malaria, perceived treatment effects, 
and reported timing of perceived treatment effects. 
    Ethical  clearance.     The study was approved by the Ethical 
Committee of the University of Antwerp, Belgium and the 
Ethical Review Committee of the Universidad Peruana 
Cayetano Heredia, Lima, Peru. During field work, all inter-
viewers followed the Code of Ethics of the American Anthro-
pological Association (AAA).  22   As proposed by the AAA, all 
interviewees were informed before the start of the interview 
about project goals, the topic and type of questions, their right 
to refuse being interviewed, interrupt the conversation at any 
time, and withdraw any given information during or after the 
interview, and the intended use of the results for scientific 
publications and reports to health authorities. Oral consent 
was preferred, because the interviewees were not put at any 
risk of being harmed physically or psychologically and the 
act of signing one’s name when providing information during 
interviews could be a potential reason for mistrust.  23  
    RESULTS 
    Socio-demographic characteristics of   P. vivax   malaria 
patients.     A total of 1,279 confirmed   P. vivax   patients (presence/
history of fever and presence of   P. vivax   asexual forms in the 
blood smears) were identified at the Paujil and Cahuide HCs 
between January 2005 and July 2007 (for patients with multiple 
vivax episodes, only the last episode was recorded). Among 
these patients, 1,072 (83.8%) had complete information on the 
number of CQ and PQ doses given. The majority of patients 
were male (61.9%; 664/1,072), and the median age was 21 years 
(range = 1–81 years). No geographic clustering was found. 
Patients’ subsistence strategies were mostly centered around 
slash and burn agriculture in combination with various other 
economic activities such as fishing, hunting, coal production, 
fish farming, logging, and gathering of certain palm leaves. 
      Perceived cause of malaria infection.    The  perceived  cause 
of the last   P. vivax   episode was asked to the 185 randomly 
selected patients in their respective communities (  Table 1  ). 
Malaria infection was mostly related to (i) mosquito biting 
(49.7%) and (ii) bad or contaminated water (35.1%). In line 1020 PEETERS GRIETENS AND OTHERS
with the information gathered in the in-depth interviews, it 
was further inquired whether or not malaria could be caused 
by drinking water; 71.4% responded affirmatively. 
        Local  conceptions  of  malaria.     In the local socio-cultural 
context, malaria is interpreted according to humoral illness 
conceptions and classified as a hot disease. The humoral 
illness theory consists of a classificatory system of interpreting 
illnesses, categorizing them according to their hot and cold 
qualities or characteristics.  24  Both categories, with their internal 
gradations, do not apply just to illnesses but also to types of 
treatment (medication and medicinal plants), food and drink, 
people (i.e., elderly versus children), states of the body (i.e., 
pregnancy and birth), activities (working versus resting), etc. 
Illness is the disruption of the natural balance or equilibrium 
of the humors in the body because of sudden (external) or 
excessive change, such as cold rain when working hard, hot 
food when the body is cold or weak, etc. These disrupting 
actions shock (inf.   chocar   | n.   choque  ) or disrupt the health 
equilibrium that balances the cold and hot humors, leading 
to weakness and/or illness. Therefore, febrile illnesses such 
as malaria lead to a state in which the body becomes too hot 
and during which the patient should avoid an excess of heat 
(i.e., working in the sun, eating certain hot meals and drinks 
such as difficult to digest meat like pork, and having sexual 
relations) or sudden cold (i.e., exposure to rain). However, 
although malaria is considered a hot disease, it initially 
undergoes a cold phase during which people experience the 
characteristic chills or cold fever. 
   Local  conceptions  of  treatment.     Regaining good health 
consists of progressively and slowly restoring the humoral 
balance and avoiding excess. A hot illness will have to be 
treated by refreshing the body progressively and will worsen 
with hot medication and/or with immediate and/or excessively 
cold medication. However, CQ-PQ treatment is interpreted as 
having hot properties because of its strength, bitterness (and 
associated purging effects), and perceived potent effects on 
the patients’ health. 
  Regarding patients’ perception of the evolution of their 
illness in relation to malaria treatment, the following can be 
highlighted: (i) patients state feeling worse with the first intake 
of treatment; (ii) almost two-thirds of the patients state feeling 
better 3 days after initiating treatment (  Table 2  ); (iii) a similar 
proportion of patients claims that the treatment shocks them 
within the first 3 days (referring to the disruption of the health 
equilibrium when the hot state of the body is aggravated by 
the perceived hot treatment;   Table 2  ); and (iv) the hot prop-
erties of malaria lead to the use of refreshing herbal drinks 
during treatment (75.7% of patients) and the prohibition of 
hot foods and activities (data not shown). This conception of 
malaria and its treatment is summarized in   Figure 2   and illus-
trated in the following excerpt from an in-depth interview: 
“My mother-in-law bought some pork and we went over for 
lunch but then, the same evening, I was shaking with malaria … 
My mother-in-law says we’re never ever going to buy pork 
again! … So much malaria with all that pork!” (mestizo farmer; 
Villa Buen Pastor). 
         Delay  and  treatment  before  consultation  at  HC.    According 
to the Adherence Survey respondents, 58.1% of patients 
sought biomedical treatment within the first 3 days of symptom 
onset, whereas an additional 20.7% sought treatment between 
day 3 and day 6; 21.2% waited for 7 or more days to seek 
treatment (data not shown). During this pre-medical phase, 
paracetamol (49.6% of the surveyed population) and some 
form of traditional treatment, such as bitter medicinal roots 
and barks, and refreshing herbs (28.3%) were used to reduce 
fever; 11.8% of respondents stated that one should not to take 
any medication or consume any special food or drink during 
this period, and only 2.4% purchased anti-malarial medication 
outside of the HC (7.9% of responses were missing). 
   Productivity  time  loss.     The median reported number of 
working days lost because of a clinical vivax attack, among the 
185 interviewed patients, was 9 (ranging from 0 to 90 days). 
   Adherence  to  current  radical  treatment.     Doses  delivered  by 
the HC.     According to the HCs’ clinical files (  Table 3  ), 77.9% 
(835/1,072) of the vivax patients that consulted at the HC 
received the full 7-day dose of PQ, and an additional 21.4% 
received between 3 and 6 days of treatment. Most vivax 
patients (97.2%) had been given the full 3-day dose of CQ. 
       Doses  reportedly  taken  according  to  Adherence  Survey 
respondents.     Of all respondents interviewed, 71.9% (133/185) 
stated that they had taken the treatment for the full 7 days 
(  Table 4  ). However, when comparing survey response to the 
HC patient records, only about one-half of the respondents 
(91/185 = 49.2%) both stated to have completed the 7-day 
treatment and had actually received the complete 7-day 
treatment from the HC. Thus, of all respondents that stated to 
adhere to the full 7-day treatment, about one in three (42/133 = 
31.6%) had not returned to the HC to retrieve the medication 
for the remaining 4 days. Furthermore, 20.2% (23/114) 
  Table  1 
    Perceived causes of malaria among   P. vivax   patients  
Answers Frequency
Cause of last malaria infection?   n %
Water 65 35.1
Mosquitoes bites 92 49.7
Don’t know 22 11.9
Other 6 3.3
Can water cause malaria?
No 50 27.0
Yes 132 71.4
Don’t know 2 1.1
Missing 1 0.5
    Total number of interviewed people (  N   = 185).   
  Table  2 
    Reported time of treatment effects after initiation of PQ treatment   
Answers Frequency
Reported time people feel better after initiating treatment   n %
0 days 0 0
1 day 8 5.1
2 days 25 15.8
3 days 99 62.7
4 days 25 15.8
6 days 1 0.6
Reported time the treatment starts to shock
Since the beginning 27 17.1
1 day 55 34.8
2 days 12 12.0
3 days 10 6.3
4 days 5 3.2
5 days 1 0.6
6 days 6 3.8
It didn’t shock me 35 22.2
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of patients having received the full dose of anti-malarial 
medication at the HC did not complete the treatment. 
Considering that 77.9% of the vivax patients consulting at the 
HC had received the full 7-day dose of PQ (  Table 3  ) and that 
20% of them did not complete it, only 62.2% of patients had 
actually taken the full course of PQ. 
         Evaluation  of  radical  treatment.        Perceived  difficulties 
for treatment adherence were evaluated in several survey 
questions; 69.9% of respondents stated that the medication 
provided at the HC shocked their health, whereas 61.2% 
claimed to have had an allergic reaction to the medication. 
Among respondents that openly admitted to having abandoned 
treatment ( N  = 37), the same major health-related reasons were 
cited, especially the fact that the treatment shocked (58.2%); 
29.1% did not state any difficulties, whereas minor reasons 
included allergies (3.6%), having recovered their health before 
the medication was finished (3.6%), and anorexia (3.6%). 
All respondents (  N   = 185) were further asked why people 
generally abandon treatment after 3 days. To this half-open 
question, major reasons given were related to the medication 
being bad for people’s health (48.7%, including the treatment 
shocks, allergies, bad for health, makes people weak and pale, 
etc.) and having recovered good health (10.8%), whereas one 
in three answered not to know any reasons (30.8%); 9.7% 
provided other responses. 
    Timing  of  treatment  abandonment.    In - depth  interviews 
on adherence showed that most non-adherent patients 
abandoned treatment after the first 3 days. Several reasons can 
account for this: (i) the progress of the illness and the effect 
of the medication make patients gradually feel better after 
3 days (  Table 2  ); (ii) the perceived shock to the body (  Table 2  ); 
and (iii) the necessity of patients having to go back to the HC 
to receive the remaining doses of medication after the first 
3 days, which implies new costs (especially transportation 
costs) and productivity time loss. 
   Relapse.     Approximately 24% of patients (45/185) stated 
to have relapsed after their last vivax malaria episode. Main 
reasons cited for relapse were eating greasy (hot) food 
(i.e., pork and chicken; 60.0% = 27/45), drinking alcohol 
(22.2% = 10/45), an infected mosquito bite (2.2% = 1/45), didn’t 
complete  treatment (2.2% = 1/45), and bad water (2.2% = 
1/45). Other causes were the rain, using ice, and too much sun 
(total of 11.1% = 5/45). 
      Use of the health promoter.      Twelve percent of all inter-
viewed patients had consulted the health promoter for their 
last vivax episode, whereas the remaining 88% went directly 
to the HC or Iquitos hospital. 
    DISCUSSION 
  According to the HCs’ records, most patients with vivax 
malaria had taken a complete treatment with CQ and PQ. 
Nevertheless, when analyzing such records against survey 
data, the proportion of patients having taken the full CQ and 
PQ course was much lower. Response bias was anticipated, 
because survey respondents generally tend to claim adher-
ence to prescribed public-health interventions, irrespective of 
their personal experience, opinions, or actions, to avoid being 
seen as negligent and/or ignorant of basic biomedical health 
ordinances. Similarly, this holds true for the under-reporting of 
traditional herbal medicine and other non-biomedical health-
seeking practices. These considerations accounted for one of 
the main reasons for using methodological triangulation. 
  Most non-adherent patients in the study area abandoned 
the treatment after or around the initial 3 days. Various factors 
account for this. Adherence is a continuous process during 
  Figure   2.       Schematic presentation of humoral illness and treatment conceptions.       
  Table  3 
    CQ and PQ doses delivered at the HCs (  N   = 1072)   
Treatment delivered Frequency
CQ doses delivered   n %
0 day  s 2 0.2
1 day 3 0.3
2 days 12 1.1
3 days 1.042 97.2
Missing 13 1.2
PQ doses delivered
< 3 days 10 0.9
3 days 170 15.9
3–7 days 49 4.6
7 days 835 77.9
Missing 8 0.7
  Table  4 
    Treatment adherence according to patients’ files (HC) and survey 
respondents  
Treatment reportedly taken (survey)
Treatment delivered by HC* Total
< 7 days 7 days   n   (%)
< 7 days 14 (0.2) 23 (20.2) 37 (20.0)
7 days 42 (0.8) 91 (79.8) 133 (71.9)
Missing 15†
Total 56 114 185
  *   Column  percentages  shown  in  parentheses.  
    †     Information missing in the HC files.   1022 PEETERS GRIETENS AND OTHERS
which the patient evaluates and re-evaluates the course of his 
illness and the perceived benefits and risks of the treatment. 
In the local context, treatment of vivax malaria can be seen as 
consisting of two phases, a first 3-day phase with CQ and PQ 
and a second 4-day phase with only PQ. During the first phase, 
patients feel extremely sick and are, therefore, most will-
ing to accept the treatment, despite its perceived side effects. 
However, during the second phase, as the illness progresses 
and the effects of the medication take hold, symptoms abate, 
diminishing the perceived benefits of continuing the remain-
ing 4 days of PQ treatment. Additionally, patients have to 
return to the HC to collect the remaining PQ tablets. This can 
be inconvenient in terms of work obligations, costing money, 
and seeming unnecessary. 
  Patients believe that the current radical treatment with CQ 
and PQ, although necessary, is bad for their health. Perceived 
allergies to the medication and/or other side effects mainly 
associated with PQ (such as gastrointestinal side effects 
including nausea, vomiting, stomach pain, etc.) are related to 
the local humoral illness conception of malaria and its cat-
egorization as a hot disease. Malaria, even in its latent form, 
produces a state of body that is too hot, and as such, the 
patient should avoid an excess of heat or sudden cold. The 
consumption of certain excessively hot foods or activities can 
all exacerbate the malaria sufferer’s condition, aggravating 
symptoms or leading to relapses. In this context, the treat-
ment falls under the category of a product inducing excessive 
heat in the body. However, despite the fact that malaria is a 
hot disease, it undergoes an initial cold phase during which 
the patient develops a cold fever. Vivax malaria symptoms 
are characterized by febrile peaks of up to 40.5°C, which are 
preceded, for a half an hour or so, by chills and rigors.  25   It can, 
therefore, be hypothesized that a hot treatment is generally 
more acceptable during the initial stage of the illness where 
it is perceived to combat the cold. After this phase is over, 
however, and malaria regains its hot qualities, the medication 
provided at the HC is considered excessive and consequently 
unhealthy. Patients, therefore, try to balance the excess heat 
with drinks and herbs to refresh the body and to counteract 
the added hot characteristics of the medication. A common 
course of treatment was to take herbal medication during 
and after the CQ and PQ treatment. Herbal medication is 
believed to be healthier than the HC’s medicine, is thought 
to facilitate a faster return to work activities, and, for part of 
the population, has the added value of being part of tradi-
tional culture. 
  A second example of the humoral illness interpretation of 
malaria is the local understanding of relapse. Of the about 
one-quarter of patients believed to have relapsed after the 
initial   P. vivax   malaria episode, a large majority attributed it 
to excessive heat or sudden cold, eating greasy food, drink-
ing alcohol, exposure to rain, ice, too much sun, etc. It is in this 
context that the high percentages of perceived allergies and 
perceived shock because of the medication have to be under-
stood. Perceived adverse effects typically start at day 2 to day 3, 
when patients feel a diminished need to continue the treat-
ment. The importance of perceived adverse effects were also 
a main reason for non-adherence in a study carried out in the 
province of Esmeraldas in Ecuador, in which adherence was 
estimated at 65.9% based on direct interviews, including clini-
cally confirmed vivax and falciparum patients.  26   A  qualitative 
study in Piura and Tumbes in Peru also cited the quick lessen-
ing of symptoms and the perceived adverse effects of treat-
ment as the main elements diminishing adherence.  27  
  The relatively low adherence to vivax malaria treatment 
can probably further be related to various general adherence 
factors, such as the length of the treatment and the inherent 
milder symptoms of vivax compared with falciparum malaria. 
However, despite the general assumption that length of treat-
ment and illness severity directly influence adherence, there 
is limited research and theory in the malaria field to corrob-
orate this.  5  ,  28   The same holds true for distance and access to 
health care. Despite harsh weather and road conditions dur-
ing the rainy season, access to the HCs is relatively easy for 
most communities along the Iquitos/Nauta road, and treat-
ment is free of charge. Furthermore, health staffs suggested 
that patients in communities with difficult access to treatment 
might be more willing to adhere out of fear of relapse, whereas 
in nearby communities, patients often opt to stop treatment as 
soon as possible because of their easy access to new medica-
tion if necessary. 
  In the present context, several possible policies encouraging 
greater adherence should be further evaluated. The combina-
tion of treatment with certain nutritional or medicinal supple-
ments may increase the perceived supplementary benefits of 
treatment, especially in a context where the use of supplemen-
tary herbal treatment is already a general practice. Increasing 
community awareness concerning the need to complete PQ 
intake to avoid further transmission to family and community 
members could further stimulate social pressure to adhere. 
Lastly, a feasible system of direct observed intake of the medi-
cation, organized at the community level (i.e., by health pro-
moters paid per patient that completes treatment), could be 
an option, requiring, however, a good supervision system and 
attractive incentives. 
 In conclusion, because PQ is the only available drug currently 
on the market for eliminating   P. vivax   hypnozoites, treatment 
adherence is essential in light of malaria-elimination strate-
gies and the prevention of parasite resistance. Understanding 
related illness and treatment conceptions among local popula-
tions is, therefore, the key to improving vivax malaria control 
in endemic regions. 
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